A Phase 2a, Randomized, Open-Label, 2-Way Crossover Study To Determine The Pharmacokinetics, Safety, And Tolerability Of Aclidinium/Formoterol 400/12 microg Fixed Dose Combination Via Almirall Inhaler And Formoterol 12 microg Via Foradil Aerolizer In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease

Trial Profile

A Phase 2a, Randomized, Open-Label, 2-Way Crossover Study To Determine The Pharmacokinetics, Safety, And Tolerability Of Aclidinium/Formoterol 400/12 microg Fixed Dose Combination Via Almirall Inhaler And Formoterol 12 microg Via Foradil Aerolizer In Patients With Moderate To Severe Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Aclidinium bromide/formoterol (Primary) ; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 29 Aug 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 21 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top